Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Integral BioSystems has received a Phase I SBIR Research Grant from the National Eye Institute to further develop its glaucoma treatment drug.
Subscribe to our email newsletter
The company’s EySite-NanoM is a sustained-release delivery system designed to offer continuous release of its therapeutic anti-glaucoma agent for preventing the peak and trough drug levels that take place with topical dosing.
It uses a sustained release delivery systems for front-of-the-eye ocular delivery with the dosing advantages of punctal plugs and drug-coated contact lenses.
Apart from manufacturing challenges, drug-eluting contact lenses affect the vision field with inherent changes in the visual actuity of the lens as the drug depletes, and punctal plugs need to be installed by a clinician.
EySite-NanoM will not interfere with a patient’s field of vision, and a clinician is not required to install it.
Integral BioSystems CEO Shikha Barman said: "This delivery system is transformational and has the potential to replace frequent and inefficient eye-drop administration for chronic ocular disorders."
Majority of ophthalmic drugs are currently administered in the form of eye-drops. With one drop, just around 5% of the drug administered is absorbed by ocular tissue, and the remaining is lost via naso-lacrimal drainage.
Integral BioSystems said EySite-NanoM leads the way to preservative-free strategies for glaucoma treatment in future therapeutic regimens, avoiding correlation with inflammation of ocular tissues.
The company partners with pharmaceutical firms to co-develop products based on its ophthalmic delivery systems, OcuSurf and EySite, both of which are patent pending.